𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study

✍ Scribed by Chi-Un Pae; Yoo-Jin Kim; Wang-Youn Won; Hee-Je Kim; Seok Lee; Chang-Uk Lee; Soo-Jung Lee; Dong-Wook Kim; Chul Lee; Woo-Sung Min; Chun-Choo Kim; In-Ho Paik; Alessandro Serretti

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
63 KB
Volume
19
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

The efficacy and tolerability of paroxetine in the treatment of depressive disorders is well known, however, its efficacy and safety for the treatment of depression in patients with cancer has been poorly studied. Therefore this study was aimed at evaluating the efficacy and tolerability of paroxetine in the treatment of depressed patients with haematological malignancy (HM).

Method

Fifty‐two patients with major depressive disorder (MDD) based on DSM‐IV criteria along with comorbid HM were allotted to an 8 week trial with a flexible‐dose regime of paroxetine in combination with their chemotherapy or supportive pharmacotherapy. The treatment response was assessed at baseline, week 2, week 4 and week 8 with the 17‐item Hamilton rating scale for depression (HAM‐D17), the Montgomery Åsberg depression rating scale (MADRS) and the clinical global impression‐severity (CGI‐S). Side effects were collected with reported adverse events and laboratory tests throughout the study period.

Results

44.2% of 52 patients completed the 8 week trial. Scores on the HAM‐D17, MADRS and CGI‐s (last observation carried forward, LOCF) at baseline were significantly reduced with a mean reduction of 30.5%, 32.8% and 39.1%, respectively, after 8 weeks treatment with paroxetine.

Conclusion

In this preliminary study, paroxetine was found to be effective and moderately tolerated in the treatment of depressed patients with HM, and the present study calls for a controlled study in this field to extend and form a framework on the psychopharmacological data in this field. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

The efficacy of reboxetine in the treatm
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
✍ P. N. Dannon; I. Iancu; L. Grunhaus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi

Duloxetine in the treatment of adolescen
Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study
✍ Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, par

Duloxetine in the treatment of irritable
Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal

Effectiveness and tolerability of paroxe
Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea
✍ Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled